BlackRock, Inc. filed a Schedule 13G with the SEC on October 27, 2026, disclosing beneficial ownership of 2,895,165 shares of Climb Bio Inc common stock as of September 30, 2026.

Key Highlights

  • Aggregate beneficial ownership: BlackRock reported beneficial ownership of 2,895,165 shares of Climb Bio Inc common stock, representing 5.0% of the class.
  • Sole voting power: BlackRock disclosed sole voting power over 2,831,010 shares, with shared voting power of 0.
  • Sole dispositive power: BlackRock reported sole dispositive power over all 2,895,165 shares, with shared dispositive power of 0.
  • Triggering date: The date of the event requiring this filing was September 30, 2026.
  • Filer classification: BlackRock, Inc. is identified as a parent holding company (type "HC"), incorporated in Delaware, with principal offices at 50 Hudson Yards, New York, NY 10001.
  • Dividends and proceeds: According to the filing, various persons have the right to receive dividends or proceeds from the sale of Climb Bio Inc common stock, and no single person's interest exceeds 5% of total outstanding shares.

BlackRock's Schedule 13G Filing for Climb Bio Inc Common Stock

BlackRock, Inc. filed a Schedule 13G on October 27, 2026, disclosing a 5.0% beneficial ownership position in Climb Bio Inc (CUSIP: 28658R106), a company headquartered at 20 William Street, Suite G50, Wellesley Hills, MA 02481. The filing states that the event requiring the disclosure occurred on September 30, 2026. BlackRock is classified as a parent holding company in the filing, and its subsidiaries and affiliates are referenced as the "Reporting Business Units."

According to the filing, the 2,895,165 shares reported as beneficially owned reflect securities held by certain business units of BlackRock and its subsidiaries and affiliates, consistent with SEC Release No. 34-39538 (January 12, 1998). The filing notes that this Schedule 13G "does not include securities, if any, beneficially owned by other business units whose beneficial ownership of securities are disaggregated from that of the Reporting Business Units in accordance with such release." BlackRock's sole voting power covers 2,831,010 shares, while sole dispositive power extends to all 2,895,165 shares. Shared voting and dispositive power are each reported as 0.

The filing was signed by Spencer Fleming, identified as Managing Director of BlackRock, Inc., on October 27, 2026. The certification states that the securities "were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control" of Climb Bio Inc. Subsidiary identification is provided in Exhibit 99, as referenced under Item 7 of the filing.

What Was Disclosed

BlackRock, Inc. disclosed a 5.0% beneficial ownership stake in Climb Bio Inc common stock, totaling 2,895,165 shares, with sole dispositive power over all reported shares and sole voting power over 2,831,010 shares, as of September 30, 2026.